- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Understanding Demodex Blepharitis Pathogenesis
Eric D. Donnenfeld, MD; discusses the importance of understanding the pathogenesis of Demodex blepharitis to reach a proper diagnosis.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of an Insights involving Eric D. Donnenfeld, MD.
Demodex is a very common eyelash mite found in most USpatients, causing blepharitis and inflammation. Many clinicians and patients are unaware of Demodex’s significant role in ocular surface disease. Educating patients about this chronic parasite is important because its role is often misunderstood.
For decades, clinicians thought Demodex was harmless. It is now knownthat blepharitis is overwhelmingly associated with Demodexinfestation. When seeing infected patients, Donnenfeld explains how eradicating Demodexcan improve their ocular surface disease.
Demodex blepharitis causes eyelid inflammation, redness, and occlusion, but patients cannot self-diagnose. Eye care professionals diagnose it readily by looking for pathognomonic cylindrical plugs called collarettes on eyelashes. Healthcare professionals must recognize collarettes indicatingDemodex blepharitis and look for them.
Previously, Demodex’s role was misunderstood and no FDA-approved treatments existed. Now an effective approved medication manages Demodex, improving ocular disease. All eye care professionals should understand Demodex’s role in blepharitis and test for it routinely.
Video synopsis is AIgenerated and reviewed by AJMC® editorial staff.
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More
